Rhabdomyolysis due to interaction of simvastatin with mibefradil

被引：96

作者：

Schmassmann-Suhijar, D

Bullingham, R

Gasser, R

Schmutz, J

Haefeli, WE

机构：

[1] Univ Basel Hosp, Div Clin Pharmacol, CH-4031 Basel, Switzerland

[2] Univ Basel Hosp, Dept Internal Med, CH-4031 Basel, Switzerland

[3] CS Associates, Palo Alto, CA USA

[4] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland

[5] Gen Practice, Basel, Switzerland

来源：

LANCET | 1998年 / 351卷 / 9120期

关键词：

D O I：

10.1016/S0140-6736(05)78613-X

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

[No abstract available]

引用

页码：1929 / 1930

页数：2

共 5 条

[1]

Horn M, 1996, ARCH DERMATOL, V132, P1254, DOI 10.1001/archderm.132.10.1254

[2] Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone [J].

Jacobson, RH ;

Wang, P ;

Glueck, CJ .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (04) :296-296

[3] In vitro comparative inhibition profiles of major human drug metabolising cytochrome p450 isozymes (CYP2C9, CYP2D6 and CYP3A4) by HMG-CoA reductase inhibitors [J].

Transon, C ;

Leemann, T ;

Dayer, P .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1996, 50 (03) :209-215

[4]

VANDERHO.TA, 1974, J BIOL CHEM, V249, P6302

[5] BIOTRANSFORMATION OF LOVASTATIN .4. IDENTIFICATION OF CYTOCHROME-P450 3A-PROTEINS AS THE MAJOR ENZYMES RESPONSIBLE FOR THE OXIDATIVE-METABOLISM OF LOVASTATIN IN RAT AND HUMAN LIVER-MICROSOMES [J].

WANG, RW ;

KARI, PH ;

LU, AYH ;

THOMAS, PE ;

GUENGERICH, FP ;

VYAS, KP .

ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1991, 290 (02) :355-361

← 1 →